Sandoz Group AG Stock

Equities

SDZ

CH1243598427

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:08 2024-07-17 EDT 5-day change 1st Jan Change
34.39 CHF -0.03% Intraday chart for Sandoz Group AG +1.15% +27.09%

Financials

Sales 2024 * 10.29B 9.11B 14.07B Sales 2025 * 10.92B 9.67B 14.94B Capitalization 16.51B 14.62B 22.57B
Net income 2024 * 709M 628M 969M Net income 2025 * 970M 859M 1.33B EV / Sales 2024 * 1.91 x
Net Debt 2024 * 3.11B 2.76B 4.26B Net Debt 2025 * 2.72B 2.41B 3.71B EV / Sales 2025 * 1.76 x
P/E ratio 2024 *
23.7 x
P/E ratio 2025 *
17 x
Employees 22,633
Yield 2024 *
1.66%
Yield 2025 *
2.12%
Free-Float 95.59%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.96%
1 week-0.32%
Current month+4.15%
1 month+6.44%
3 months+20.78%
6 months+16.50%
Current year+25.24%
More quotes
1 week
33.85
Extreme 33.85
35.50
1 month
31.71
Extreme 31.71
35.50
Current year
25.33
Extreme 25.33
35.50
1 year
22.70
Extreme 22.7
35.50
3 years
22.70
Extreme 22.7
35.50
5 years
22.70
Extreme 22.7
35.50
10 years
22.70
Extreme 22.7
35.50
More quotes
Date Price Change Volume
24-07-17 34.39 -0.03% 698 864
24-07-16 34.4 +0.26% 577,073
24-07-15 34.31 -2.14% 722,007
24-07-12 35.06 -0.28% 769,929
24-07-11 35.16 +3.41% 1,170,163

Delayed Quote Swiss Exchange, July 17, 2024 at 09:27 am

More quotes
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
38.42 USD
Average target price
40.71 USD
Spread / Average Target
+5.98%
Consensus

Quarterly revenue - Rate of surprise